Sign in

Davide Campari-Milano N.V. CPR.MI

Price 5.80 EUR
as of 2026-09-04
49/100
Mixed
Quality47
Growth63
Balance-sheet strength51
Valuation46
Momentum35
Income65

Composite 49/100; the shares have moved about 31% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.

Strongest counter-signal

Momentum ranks 35/100 — a moderate mark against it.

Case for

Income ranks 65/100 — a moderate point in its favour. Growth ranks 63/100 — a moderate point in its favour. Balance-sheet strength ranks 51/100 — a slight point in its favour.

Case against

Momentum ranks 35/100 — a moderate mark against it. Valuation ranks 46/100 — a slight mark against it. Quality ranks 47/100 — a slight mark against it.

What the company does Davide Campari-Milano N.V. (CPR.MI) is an Italian beverage company founded in 1860, marketing global spirits and non-alcoholic brands such as Aperol, Campari, Wild Turkey, Grand Marnier, and SKYY Vodka across 190+ markets.

Key financials Revenue fell -2.8% while gross margin held at 60.3% and net margin was 11.4%. ROE is 8.6%, ROA 4.8%, and ROCE 4.4%. Debt/Equity is 0.70 and net debt/EBITDA is 2.65x, with interest coverage at 2.83x and current ratio 2.22.

Stock health SideraVIA scores Weak Quality (40.0) and Valuation (55.0), with Momentum at 39.3 and Income at 66.0. Piotroski F-Score is 3/9 and Altman Z is 2.46. RSI(14) is 64.50.

Price vs fair value CPR.MI trades at a PREMIUM of 12.30% to our fair-value estimate of 5.19 and a discount of 15.98% to the 12-month target of 6.87. - Analysts cite Aperol-led growth as a key driver (WSJ 2026-07-30). - Bourbon softness in the U.S. offsets gains, pressuring near-term sentiment (WSJ 2026-07-29). - Valuation percentile 55.0/100 suggests fair pricing within the screened universe.

Looking forward Forward P/E is 17.12x and PEG is 0.83, implying modest earnings growth expectations. Dividend yield is 1.7% with a conservative 22.4% payout ratio.

sideravia.comEvery stock argues both sides.
Research, not advice · sideravia.com/conflicts — read the policy

This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.

Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.